These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 18691886)

  • 1. Physiochemical drug properties associated with in vivo toxicological outcomes.
    Hughes JD; Blagg J; Price DA; Bailey S; Decrescenzo GA; Devraj RV; Ellsworth E; Fobian YM; Gibbs ME; Gilles RW; Greene N; Huang E; Krieger-Burke T; Loesel J; Wager T; Whiteley L; Zhang Y
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4872-5. PubMed ID: 18691886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
    Price DA; Blagg J; Jones L; Greene N; Wager T
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):921-31. PubMed ID: 19519283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating metabolism and toxicity in multi-organ systems.
    Madden S; Bach PH
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):66-72. PubMed ID: 11727325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening.
    Siraki AG; Chevaldina T; Moridani MY; O'Brien PJ
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):118-25. PubMed ID: 14982155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking toxicity and chemistry: think globally, but act locally?
    Johnson DE; Smith DA; Park BK
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):33-5. PubMed ID: 14982145
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure activity relationship in toxicology.
    Vereczkey L
    Acta Physiol Hung; 1995; 83(1):47-50. PubMed ID: 7660836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?
    Kroll F; Dreger M
    Future Med Chem; 2010 Nov; 2(11):1613-7. PubMed ID: 21428831
    [No Abstract]   [Full Text] [Related]  

  • 8. [Strategy of molecular drug design: activity and druggability].
    Guo ZR
    Yao Xue Xue Bao; 2010 May; 45(5):539-47. PubMed ID: 20931752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methodological characteristics of the preclinical study of the safety of drug preparations for children].
    Mal'tseva LF; Muratova GP; Motovilova VG; Sirinova NA
    Farmakol Toksikol; 1988; 51(4):96-100. PubMed ID: 3191987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates.
    Olaharski AJ; Uppal H; Cooper M; Platz S; Zabka TS; Kolaja KL
    Toxicol Lett; 2009 Jul; 188(2):98-103. PubMed ID: 19446241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound toxicity screening and structure-activity relationship modeling in Escherichia coli.
    Planson AG; Carbonell P; Paillard E; Pollet N; Faulon JL
    Biotechnol Bioeng; 2012 Mar; 109(3):846-50. PubMed ID: 22038678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What have we learned from pre-clinical juvenile toxicity studies?
    Bailey GP; Mariën D
    Reprod Toxicol; 2009 Sep; 28(2):226-9. PubMed ID: 19446432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The current requirements for the preclinical study of the safety of new drugs].
    Arzamastsev EV; Liubimov BI
    Eksp Klin Farmakol; 1995; 58(3):7-12. PubMed ID: 7663306
    [No Abstract]   [Full Text] [Related]  

  • 15. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preclinical investigation and testing of nontoxicity of drugs in the pharmaceutrial industry].
    Tripod J
    Schweiz Med Wochenschr; 1968 Aug; 98(31):1152-8. PubMed ID: 4236567
    [No Abstract]   [Full Text] [Related]  

  • 17. Single dose toxicity and repeated dose toxicity studies: introductory remarks.
    Kurokawa Y; Matsuzawa T
    J Toxicol Sci; 1996 Dec; 21(5):413-6. PubMed ID: 9035047
    [No Abstract]   [Full Text] [Related]  

  • 18. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 19. [Problems in the preclinical study of drug safety].
    Liubimov BI; Shashkina LF; Gus'kova TA
    Farmakol Toksikol; 1981; 44(4):389-95. PubMed ID: 7286193
    [No Abstract]   [Full Text] [Related]  

  • 20. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.